Athira Pharma, Inc. (ATHA)

US — Healthcare Sector
Peers: ASMB  TIL  SPRO  CTMX  CCCC  PRLD  TSHA  FHTX  ALGS 

Automate Your Wheel Strategy on ATHA

With Tiblio's Option Bot, you can configure your own wheel strategy including ATHA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ATHA
  • Rev/Share 0.0248
  • Book/Share 0.8182
  • PB 0.4644
  • Debt/Equity 0.0318
  • CurrentRatio 10.8078
  • ROIC -1.879

 

  • MktCap 14986934.0
  • FreeCF/Share -1.8085
  • PFCF -0.212
  • PE -0.2482
  • Debt/Assets 0.0286
  • DivYield 0
  • ROE -1.394

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade ATHA Mizuho Outperform Neutral $5 $0.5 Sept. 19, 2024
Initiation ATHA Rodman & Renshaw -- Buy -- $22 Aug. 19, 2024

News

Athira Pharma Announces Reverse Stock Split
ATHA
Published: September 11, 2025 by: GlobeNewsWire
Sentiment: Neutral

BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it will effect a 10-for-1 reverse stock split of Athira's issued and authorized common stock. Athira's stockholders previously approved the reverse stock split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split at the Company's Annual Meeting of Stockholders held on May 29, 2025.

Read More
image for news Athira Pharma Announces Reverse Stock Split
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
ATHA
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development

Read More
image for news Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

About Athira Pharma, Inc. (ATHA)

  • IPO Date 2020-09-18
  • Website https://www.athira.com
  • Industry Biotechnology
  • CEO Mark J. Litton
  • Employees 26
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.